Abstract
BackgroundOvarian cancer greatly threatens the general health of women worldwide. Implementation of predictive prognostic biomarkers aids in ovarian cancer management.MethodsUsing online databases, the general expression profile, target-disease associations, and interaction network of PAWR were explored. To identify the role of PAWR in ovarian cancer, gene correlation analysis, survival analysis, and combined analysis of drug responsiveness and PAWR expression were performed. The predictive prognostic value of PAWR was further validated in clinical samples.ResultsPAWR was widely expressed in normal and cancer tissues, with decreased expression in ovarian cancer tissues compared with normal tissues. PAWR was associated with various cancers including ovarian cancer. PAWR formed a regulatory network with a group of proteins and correlated with several genes, which were both implicated in ovarian cancer and drug responsiveness. High PAWR expression denoted better survival in ovarian cancer patients (OS: HR = 0.84, P = 0.0077; PFS, HR = 0.86, P = 0.049). Expression of PAWR could predict platinum responsiveness in ovarian cancer and there was a positive correlation between PAWR gene effect and paclitaxel sensitivity. In 12 paired clinical samples, the cancerous tissues exhibited significantly lower PAWR expression than matched normal fallopian tubes. The predictive prognostic value of PAWR was maintained in a cohort of 50 ovarian cancer patients.ConclusionsHigh PAWR expression indicated better survival and higher drug responsiveness in ovarian cancer patients. PAWR could be exploited as a predictive prognostic biomarker in ovarian cancer.
Highlights
Ovarian cancer greatly threatens the general health of women worldwide
Regulatory network of PAWRBy exploring the Gene Resource of the National Center for Biotechnology Information, we identified 80 proteins that might interact with PRKC apoptosis WTI regulator (PAWR)
PAWR expression indicates drug responsiveness of ovarian cancer Since platinum agents constitute the standard of chemotherapy for ovarian cancer [1], we explored Dependency Map portal (DepMap) to identify the gene effect of PAWR on platinum responsiveness
Summary
Ovarian cancer greatly threatens the general health of women worldwide. Implementation of predictive prognostic biomarkers aids in ovarian cancer management. Ovarian cancer ranks seventh the most common cancer, causing 152,000 deaths annually worldwide (4.3% of all cancer deaths), and the 5-year survival rate for ovarian cancer has remained unchanged for decades [1]. The introductions of platinum in 1976 and paclitaxel in 1993 have greatly improved the outcomes of ovarian cancer patients [1,2,3]. The majority of patients develop resistance and recurrence [1, 5]. Implementation of predictive prognostic biomarkers could facilitate the management of ovarian cancer [1, 4,5,6,7]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
